CanPredict(肺)模型:基于1967万人开发与验证的肺癌风险预测模型
模型在验证队列中Harrell's C统计量为0·90和0·87,优于其他七种模型,有望用于英国初级保健人群的风险分层和靶向筛查。
要点
- CanPredict(肺)模型在内部验证中Harrell's C为0·90,外部验证为0·87。
- 模型在5年、6年和10年预测期内的区分度、校准度和净获益均优于其他七种模型。
- 在筛查相同数量高危个体时,模型比英国推荐的LLPv2和PLCOM2012检出更多肺癌病例。
核心结论
- CanPredict(肺)模型在开发和内外部验证中表现出优秀的区分度和校准度,有潜力用于英国初级保健人群的肺癌风险分层和高危个体筛选。
研究设计与样本
- 回顾性、基于人群的队列研究,使用QResearch(2005年1月1日至2020年3月31日)和CPRD Gold(2004年1月1日至2015年1月1日)两个英国初级保健数据库的链接电子健康记录。
- 使用Cox比例风险模型开发CanPredict(肺)模型,主要结局为肺癌的 incident 诊断。
主要发现
- 最终模型预测因子包括社会人口学特征(年龄、性别、种族、Townsend评分)、生活方式因素(BMI、吸烟和饮酒状态)、合并症、肺癌家族史和其他癌症个人史。
- 模型在QResearch验证队列中解释时间至肺癌诊断变异的R2D为65%,在CPRD验证队列中为59%;Harrell's C统计量分别为0·90和0·87,D统计量分别为2·8和2·4。
- 在两种比较方法下,CanPredict(肺)模型在5年、6年和10年三个预测期内的区分度、校准度和净获益均优于其他七种肺癌风险预测模型。
- 在筛查相同数量高危个体时,CanPredict(肺)模型比英国当前推荐的LLPv2和PLCOM2012模型检出更多肺癌病例,敏感性更高。
关键数值与推荐
- 模型在QResearch验证队列中Harrell's C统计量为0·90,D统计量为2·8,R2D为65%。
- 模型在CPRD验证队列中Harrell's C统计量为0·87,D统计量为2·4,R2D为59%。
临床怎么用
- 若该模型被推荐在初级保健中实施,可利用初级保健电子健康记录中的信息计算个体风险,识别高危人群进入肺癌筛查项目。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lung cancer is the second most common cancer in incidence and the leading cause of cancer deaths worldwide. Meanwhile, lung cancer screening with low-dose CT can reduce mortality. The UK National Screening Committee recommended targeted lung cancer screening on Sept 29, 2022, and asked for more modelling work to be done to help refine the recommendation. This study aims to develop and validate a risk prediction model-the CanPredict (lung) model-for lung cancer screening in the UK and compare the model performance against seven other risk prediction models. METHODS: For this retrospective, population-based, cohort study, we used linked electronic health records from two English primary care databases: QResearch (Jan 1, 2005-March 31, 2020) and Clinical Practice Research Datalink (CPRD) Gold (Jan 1, 2004-Jan 1, 2015). The primary study outcome was an incident diagnosis of lung cancer. We used a Cox proportional-hazards model in the derivation cohort (12·99 million individuals aged 25-84 years from the QResearch database) to develop the CanPredict (lung) model in men and women. We used discrimination measures (Harrell's C statistic, D statistic, and the explained variation in time to diagnosis of lung cancer [R2D]) and calibration plots to evaluate model performance by sex and ethnicity, using data from QResearch (4·14 million people for internal validation) and CPRD (2·54 million for external validation). Seven models for predicting lung cancer risk (Liverpool Lung Project [LLP]v2, LLPv3, Lung Cancer Risk Assessment Tool [LCRAT], Prostate, Lung, Colorectal, and Ovarian [PLCO]M2012, PLCOM2014, Pittsburgh, and Bach) were selected to compare their model performance with the CanPredict (lung) model using two approaches: (1) in ever-smokers aged 55-74 years (the population recommended for lung cancer screening in the UK), and (2) in the populations for each model determined by that model's eligibility criteria. FINDINGS: There were 73 380 incident lung cancer cases in the QResearch derivation cohort, 22 838 cases in the QResearch internal validation cohort, and 16 145 cases in the CPRD external validation cohort during follow-up. The predictors in the final model included sociodemographic characteristics (age, sex, ethnicity, Townsend score), lifestyle factors (BMI, smoking and alcohol status), comorbidities, family history of lung cancer, and personal history of other cancers. Some predictors were different between the models for women and men, but model performance was similar between sexes. The CanPredict (lung) model showed excellent discrimination and calibration in both internal and external validation of the full model, by sex and ethnicity. The model explained 65% of the variation in time to diagnosis of lung cancer R2D in both sexes in the QResearch validation cohort and 59% of the R2D in both sexes in the CPRD validation cohort. Harrell's C statistics were 0·90 in the QResearch (validation) cohort and 0·87 in the CPRD cohort, and the D statistics were 2·8 in the QResearch (validation) cohort and 2·4 in the CPRD cohort. Compared with seven other lung cancer prediction models, the CanPredict (lung) model had the best performance in discrimination, calibration, and net benefit across three prediction horizons (5, 6, and 10 years) in the two approaches. The CanPredict (lung) model also had higher sensitivity than the current UK recommended models (LLPv2 and PLCOM2012), as it identified more lung cancer cases than those models by screening the same amount of individuals at high risk. INTERPRETATION: The CanPredict (lung) model was developed, and internally and externally validated, using data from 19·67 million people from two English primary care databases. Our model has potential utility for risk stratification of the UK primary care population and selection of individuals at high risk of lung cancer for targeted screening. If our model is recommended to be implemented in primary care, each individual's risk can be calculated using information in the primary care electronic health records, and people at high risk can be identified for the lung cancer screening programme. FUNDING: Innovate UK (UK Research and Innovation). TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Liao W, Coupland CAC, Burchardt J, et al. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models. Lancet Respir Med. 2023. PMID: 37030308. doi:10.1016/S2213-2600(23)00050-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。